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Abstract
Purpose Activation of intestinal epithelial cell (IEC)
nuclear factor κB (NFκB) and the consequent chemokine
upregulation are crucial events in inflammatory bowel
disease (IBD) pathogenesis. Not much is known about the
consequences of NFκB inhibition in terms of chemokine
expression in intestinal cells. Therefore, we aimed to
evaluate the efficacy of compounds known to disrupt the
NFκB pathway on NFκB transcriptional activity and
CXCL8 and CXCL10 gene expression in intestinal cell
lines.
Methods The influence of NFκB inhibitors (dexamethasone,
pyrrolidine dithiocarbamate (PDTC) and BAY 11-7082) on
IL-1β-inducedNFκB transcriptional activitywas investigated
by transient transfection of Caco-2 cells with an NFκB-
secreted alkaline phosphatase reporter plasmid. Il-1β stimu-
lated CXCL8 and CXCL10 mRNA and protein expression
and was studied in Caco-2 and HT29 cells in the presence
and absence of the NFκB inhibitors by quantitative real-time
polymerase chain reaction and enzyme-linked immuno-
sorbent serologic assay, respectively. To reveal alternative
signalling cascades, experiments were also performed in the
presence of the p38MAPK inhibitor SB 203580 and the
ERK inhibitor PD 98059.
Results Dexamethasone did not downregulate chemokine
expression sufficiently, probably due to a lack of glucocor-
ticoid receptors in these cells. While BAY11-7082 inhibited
chemokine expression, PDTC led to a paradoxical upregu-
lation of CXCL8 in Caco-2 cells, which could be prevented
by inhibition of p38MAPK.
Conclusion These data explain the frequentunresponsiveness
ofIBDtoglucocorticoidtreatmentandsuggestthatalternative
NFκBinhibitioninIECsmightbeofuseinIBDtherapy.Drug
developmentbasedonmeasuringanti-NFκBactivitymightbe
misleading and should therefore also include studies on
relevant gene products.
Keywords NFκB.Intestinalepithelialcells.CXCL10.
CXCL8.PDTC
Introduction
In the past few years, there has been increasing interest in
how cytokines, bacteria and bacterial polymers induce
intestinal epithelial cell (IEC) gene expression. In IECs,
gene expression must be tightly regulated to avoid
overreaction to normal microbial flora while at the same
time remaining responsive to harmful pathogens. Nuclear
factor κB( N F κB) is a crucial player in maintaining
intestinal barrier integrity since its tonic stimulation is
essential for defensin production [1]. On the other hand,
NFκB is involved in the transcriptional activation of several
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DOI 10.1007/s00384-009-0847-3genes involved in mucosal inflammation and in contrast to
normal mucosa is activated, both in macrophages and in
epithelial cells of inflamed intestinal mucosa [2], suggesting
a prominent role in inflammatory bowel disease (IBD)
pathogenesis.
The NFκB family is comprised of a group of transcription
factors defined in part by their ability to bind a specific DNA
sequence first identified in the enhancer of the immuno-
globulin κ light chain gene [3, 4]. NFκB exists as a
heterodimer comprising RelA (p65) and NFκB1 (p50)
subunits in most cells; this heterodimer is the most potent
gene transactivator of the NFκB family [5]. NFκBi s
activated by a variety of agents, such as cytokines, growth
factors, Tcell mitogens, oxidative stress, bacteria, viruses and
their products. Upon activation by various stimuli, NFκB
transcriptionally regulates many cellular genes involved in
early inflammatory responses, including the chemokines
CXCL8 [6] and CXCL10 [7].
CXCL8 (IL-8) is a proinflammatory CXC chemokine
associated with the promotion of neutrophil chemotaxis and
degranulation [8]. CXCL8 protein is secreted by a variety
of cell types, including IECs [9, 10]. CXCL8 has also been
shown to play an important but non-specific role in the
pathogenesis of IBD, and its mRNA has been shown to be
restricted to areas with histological signs of inflammatory
activity and mucosal destruction [11].
CXCL10 is a CXC chemokine that binds to the CXCR3
chemokine receptor, expressed mainly by activated CD4
+
memory T cells, which produce a T helper cell 1 pattern of
cytokine production [12]. CXCL10 is also known for its
anti-angiogenic properties in cancers [13]. It has also been
shown that IECs express CXCL10 mRNA, suggesting that
the intestinal epithelium can play a role in modulating
physiologic and pathologic T cell-mediated mucosal
inflammation [14].
Increased NFκB activity was found in the IECs of IBD
patients [2], suggesting that targeting NFκB activity in
these cells might be an attractive goal for therapeutic
intervention. Although glucocorticoids are known to inhibit
NFκB activity [15], not much is known about their effect in
IECs in terms of expression of inflammation-related genes.
The same is true for other NFκB-inhibiting compounds like
pyrrolidine dithiocarbamate (PDTC) and BAY11-7082, an
irreversible inhibitor of IκBα phosphorylation. IL-1β is a
potent inducer of NFκB. High concentrations of IL-1β are
found both in Crohn’s disease and ulcerative colitis
intestine [16]. Previous studies have shown that CXCL8
[9] and CXCL10 [7] are upregulated by IL-1β in intestinal
cells. We aimed, therefore, to test the efficacy of different
inhibitors of NFκB on IL-1β-induced NFκB activity and
CXCL8 and CXCL10 expression in an intestinal model
system, utilising the established intestinal cell lines Caco-2
and HT29.
Materials and methods
Reagents
Recombinant IL-1β was purchased from Roche Applied
Science (Mannheim, Germany). p38 MAPK inhibitor
SB203580, MEK inhibitor PD98059 and BAY 11-7082, a
specific inhibitor of NFκB, were purchased from Calbiochem
(San Diego, CA, USA), and the NFκB inhibitor PDTC was
purchased from Sigma-Aldrich (Germany).
Cell culture and stimulation protocols
The human colon adenocarcinoma cell lines Caco-2 and
HT29 were obtained from DPZ (Braunschweig, Germany).
Caco-2 cells were grown in Eagle’s minimal essential
medium (BioWhittaker) containing 20% foetal calf serum
(FCS) supplemented with 100 U/ml each of penicillin and
streptomycin and 1% non-essential amino acids at 37°C with
5% CO2. HT29 cells were grown in Roswell Park Memorial
Institute medium containing 10% FCS and 100 U/ml
penicillin and streptomycin at 37°C with 5% CO2.
Assay for activation of NFκB
Transient transfection with pNFκB-secreted alkaline phos-
phatase (SEAP; a reporter plasmid in which NFκBp r o m o t e r
elements are linked to the gene coding for secretory alkaline
phosphatase) was used for assaying NFκBa c t i v i t y .
Caco-2 cells were plated in 24-well plates 24 h before
transfection (Nunc, Roskilde, Denmark) at a density of
50,000/well in 1 ml medium. After 24 h, the cells were
transfected using the non-liposomal formulation FuGENE
(Roche Molecular Biochemicals, Mannheim, Germany). On
the day of transfection, fresh medium was added. FuGENE
was added to the plasmid DNA at a ratio of 3 µl/µg DNA.
FuGENE was pre-diluted in 100 µl serum-free medium and
added dropwise to the concentrated plasmid DNA. After
15 min at room temperature, the mixture was added to the
cells. The cells received 200 ng pNFκB-SEAP (BD
Biosciences, Clontech, Palo Alto, CA, USA)/well.
Twenty-four hours after transfection, the cells were treated
with PDTC (0.2, 2 and 20 µg/ml, which are equivalent to
final concentrations of 1.2, 12 and 120 μM), BAY11-7082
(1, 10 and 100 μM), SB203580 and PD98059 for 1 h and
then stimulated with IL-1β (1 ng/ml) for 6 h. Finally, cell
supernatants were collected, and SEAP assays were
performed as per the manufacturer’s protocol.
RNA and protein expression studies
For stimulation, IECs were plated into 6-well plates at a
density of 5×10
5 cells per well and grown until they
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stimulation, cells were pre-treated with one of the following:
dexamethasone (1 μM), PDTC (0.2, 2 or 20 µg/ml), BAY11-
7082 (1, 10 or 100 µM), SB203580 (10 µM) or PD98059
(10 µM). Cells were then stimulated with IL-1β (1 ng/ml) for
either 1 or 4 h for mRNA expression studies or for 24 h for
enzyme-linked immunosorbent serologic assay (ELISA)
assays.
RNA was isolated using the Qiagen RNeasy Mini Kit
(Qiagen, Hilden, Germany), according to the manufac-
turer’s protocol. The RNA concentration was determined
photometrically using a Gene Quant RNA/DNA calculator
(Pharmacia, Freiburg, Germany). RNA was subsequently
used for real-time polymerase chain reaction (PCR).
Reverse transcription of mRNA was performed using 1 µg
of total cellular RNA, as described previously [17].
PCR was carried out using gene-specific primers
(Invitrogen, Karlsruhe, Germany) for human CXCL8
(forward 5′-ATG ACT TCC AAG CTG GCC G-3′, reverse
5′-GCT GCA GAA ATC AGG AAG GC-3′), CXCL10
(forward 5′-CCA GAA TCG AAG GCC ATC AA-3′,
reverse 5′-CAT TTC CTT GCT AAC TGC TTT CAG-3′)
and β-actin (forward 5′-CTG GCA CCC AGC ACA ATG-3′,
reverse 5′-CCG ATC CAC ACG GAG TAC TTG-3′)i na n
ABI Prism 7000 system.
PCR reactions were set up with Sybr® Green PCR
Mastermix, containing 0.3 µmol/l of each primer and 1 µl
of reverse transcription product in a 25-µl volume. A two-
step amplification protocol was chosen, consisting of initial
denaturation at 95°C for 10 min followed by 45 cycles of
15 s denaturation at 95°C and 30 s annealing/extension at
60°C. Finally, a dissociation protocol was performed to
control for specificity of amplification products. Relative
expression of each chemokine was then calculated using the
comparative threshold-cycle method, as described earlier
[18]. mRNA gene expression is presented as fold increase
calculated inrelationtounstimulatedcells,after normalisation
against β-actin. Glucocorticoid receptor (GR) mRNA content
was quantified in Caco-2 and HT29 cells as described
previously [18].
Supernatants of Caco-2 and HT29 cultures were collected
24 h after stimulation with IL-1β, and concentrations of
CXCL8 and CXCL10 in the supernatants were measured by
ELISA (Rnd Systems, Wiesbaden, Germany), following
protocols provided by the manufacturer.
Statistical analysis
Statistical analyses were carried out using the Prism
software packet (version 3.0, Graphpad Software, San
Diego, CA, USA). Comparisons between two or more
treatment groups were made with the unpaired t test or
analysis of variance, where appropriate. In case of RNA
expression, a log transformation was performed beforehand.
Statistical differenceswere regarded assignificant ata p value
below 0.05. Data are expressed as means±standard error of
the mean.
Results
PDTC and BAY11-7082 inhibit IL-1β-mediated
pNFκB-SEAP reporter gene activity in Caco-2 cells
In order to show whether PDTC and BAY11-7082 could
function in inhibiting NFκB in Caco-2 cells, we performed
reporter assays utilising an NFκB-SEAP reporter, which
harbours NFκB binding elements. IL-1β treatment resulted
in a 4.01±0.416-fold increase in reporter gene activity. This
induction was inhibited in a dose-dependent manner by
PDTC and BAY11-7082. Both stimulated and spontaneous
NFκB activities were half-maximally inhibited by PDTC at
a range between 0.2 and 2 µg/ml and by BAY11-7082
between 1 and 10 µM (Fig 1).
Effect of dexamethasone on cytokine-mediated CXCL8
and CXCL10 mRNA and protein expression
Chemokine mRNA and protein levels were induced by IL-
1β. Dexamethasone served to reduce IL-1β-induced
CXCL8 mRNA to 82.7±0.5% when compared to an
untreated control. However, although there was a trend,
there was no significant reduction of CXCL8 protein by
dexamethasone treatment (Fig 2a). IL-1β-induced CXCL10
mRNA expression was reduced to 81.3±9.4% of control
levels in the presence of dexamethasone. Also, CXCL10
protein levels were not significantly downregulated by
dexamethasone (Fig. 2b). In HT29 cells, dexamethasone
had no influence on CXCL8 or CXCL10 expression, either
at the mRNA or protein level (data not shown).
Glucocorticoid receptor (GR) mRNA expression in Caco-2
and HT29 cells
GR was shown to be expressed in both cell lines. However,
its expression level was extremely low (four orders of
magnitude lower) in HT29 cells compared to Caco-2 cells
(Fig. 3).
PDTC and BAY11-7082 effects on IL-1β-mediated
CXCL8 mRNA expression and protein secretion
in Caco-2 cells
PDTC, a known inhibitor of NFκB, was expected to inhibit
IL-1β-induced CXCL8 mRNA expression, as CXCL8
expression is regulated by NFκB. To prove this, CXCL8
Int J Colorectal Dis (2010) 25:323–333 325mRNA and protein expression levels were measured in IL-
1β-stimulated Caco-2 cells pre-treated with PDTC.
Surprisingly, IL-1β induced CXCL8 mRNA expression
was enhanced by PDTC in a dose-dependent manner. IL-1β
led to a 117±9.1-fold increase in CXCL8 mRNA, which
was enhanced to 150±21.6- and 262±62.35-fold increases
in the presence of PDTC at 2 and 20 μg/ml, respectively.
This observation was also confirmed at the protein level by
ELISA of culture supernatants. PDTC alone did not
stimulate CXCL8 expression (Fig. 4a).
In contrast, BAY11-7082, a specific inhibitor of IκB
phosphorylation, inhibited IL-1β-mediated CXCL8 mRNA
expression and protein secretion in a dose-dependent
manner. IL-1β-induced CXCL8 mRNA expression increased
by 120.85±33.7-fold after 1 h. In the presence of BAY11-
7082 at concentrations of 1, 10 and 100 μM, IL-1β-induced
CXCL8 mRNA levels were inhibited to 119.02±31.35-,
8.19±3.73- and 0.97±0.15-fold increases, respectively.
CXCL8 secretion induced by IL-1β reached 522.49±
46.68 pg/ml after 24 h. In the presence of BAY11-7082 (1,
10 and 100 μM), IL-1β-induced CXCL8 protein secretion
was inhibited to 429.17±17.09, 328.98±21.81 and 244.84±
5.67 pg/ml, respectively (Fig. 4b).
Comparison of the effects of the NFκB inhibitor PDTC
and MAP kinase inhibitors SB203580 and PD98059
on IL-1β-mediated CXCL8 mRNA expression and protein
secretion in Caco-2 and HT29 cells
Since IL-1β-mediated CXCL8 gene expression is also
under the control of MAP kinases, we examined the effect
of the MAPK inhibitors SB203580 (p38 MAPK inhibitor)
and PD98059 (MEK inhibitor) on IL-1β-induced CXCL8
gene expression in Caco-2 and HT29 cells and compared
these effects with that of PDTC. Pre-treatment of both
Caco-2 and HT29 cells with SB203580 (10 μM) led to a
significant reduction in IL-1β-induced CXCL8 mRNA
expression and protein secretion. In Caco-2 cells, IL-1β
(1 ng/ml) increased CXCL8 mRNA levels by 19.75±2.52-
fold, which was reduced to 7.52±0.77-fold in the presence
of SB203580. IL-1β-induced CXCL8 secretion in Caco-2
cells was reduced from 286.79±32.99 to 55.50±34.09 pg/ml
in the presence of SB203580 (10 μM). PD98059 also
inhibited IL1-β-induced mRNA and protein expression by
approximately50%.AcombinationofbothPDTC(20μg/ml)
and SB203580 (10 μM) did not inhibit IL-1β-induced
CXCL8 mRNA expression or protein secretion in Caco-2
cells. However, PDTC-mediated enhancement of IL-1β-
induced CXCL8 mRNA expression and protein secretion
was inhibited by SB203580, suggesting a role for p38 MAPK
(Fig. 5a).
We then wondered whether this enhancement effect of
PDTC was cell-line dependent, so we used HT29 cells to
check the effect of PDTC on IL-1β-mediated CXCL8
mRNA expression and protein secretion. In the case of
HT29 cells, PDTC did not inhibit IL-1β-induced CXCL8
gene expression. It also did not enhance CXCL8 expres-
sion, as was the case for Caco-2 cells. In HT29 cells,
CXCL8 was induced 11.49±2.39-fold by IL-1β, which was
reduced to 2.03±0.59-fold in the presence of SB203580
and to 2.26±0.59-fold in the presence of PD98059. IL-1β-
induced CXCL8 protein levels in HT29 cells were reduced
from 5,163.30±777.04 to 1,157.72±179.59 and 1,718.86±
166.67 pg/ml in the presence of SB203580 and PD98059,
respectively (Fig. 5b).
Fig. 1 Dose-dependent effects of pyrrolidine dithiocarbamate (PDTC)
(a) and BAY11-7082 (b) on IL-1β-mediated pNFκB-secreted alkaline
phosphatase (SEAP) reporter gene activity in Caco-2 cells. Caco-2
cells were transiently transfected with pNFκB-SEAP plasmid.
Twenty-four hours after transfection, cells were pre-treated for 1 h
with increasing concentrations of PDTC or BAY11-7082, as indicated.
After 1 h, cells were stimulated with IL-1β or phosphate buffer
solution as a control. Six hours after stimulation, cell supernatants
were collected, and SEAP activity was measured. Data are shown as
means±standard error of the mean of four individual experiments
performed in duplicate for each sample. Asterisk corresponds to p<0.05
compared to IL-1β stimulation alone
326 Int J Colorectal Dis (2010) 25:323–333Comparison of the effects of the NFκB inhibitor PDTC
and MAP kinase inhibitors SB203580 and PD98059
on IL-1β-mediated CXCL10 mRNA expression
and protein secretion in Caco-2 and HT29 cells
In contrast to CXCL8, IL-1β-induced CXCL10 expression
wasdownregulatedbyPDTCinCaco-2cells.IL-1β(1ng/ml)
induced a 55.89±4.84-fold increase in CXCL10 mRNA,
which was reduced to 45.42±4.66-, 9.51±0.72-, 17.03±3.21-
and 9.94±1.30-fold increases in the presence of PDTC
(20 μg/ml), SB203580 (10 μM), PD98059 (10 μM) and
SB203580 (10 μM) together with PDTC (20 μg/ml),
respectively (Fig. 6a). IL-1β-induced CXCL10 secretion in
Caco-2 cells was reduced from 220.66±13.86 to 134.33±
28.42, 84.46±16.82, 150.66±6.06 and 93.21±23.21 pg/ml
in the presence of PDTC, SB203580, PD98059 and
SB203580 and PDTC together, respectively.
In HT29 cells, CXCL10 mRNA expression and protein
secretion induced by IL-1β were inhibited significantly by
PDTC. IL-1β-induced CXCL10 mRNA by 11.49±2.39-
fold. In the presence of the inhibitors PDTC and SB203580,
IL-1β-induced CXCL10 mRNA expression was reduced to
5.12±1.50 and 10.76±1.15, respectively. Surprisingly,
PD98059, either alone or in the presence of IL-1β, led to
an upregulation (up to 46.12±10.97-fold) of CXCL10
mRNA, but this effect was not seen at the level of IL1β-
induced CXCL10 protein secretion. In the presence of
PDTC, SB203580 and PD98059, IL-1β-induced CXCLl0
protein secretion was reduced from 86.88±26.83 to 34.93±
10.83, 8.70±4.38 and 14.54±14.54 pg/ml, respectively
(Fig. 6b).
Discussion
Steroids are known to inhibit NFκB activity, both by direct
protein–protein interaction with the GR [19] and induction
Fig. 2 Influence of dexametha-
sone on IL-1β-induced CXCL8
(a) and CXCL10 (b)m R N A( left
panel) and protein (right panel)
expression. Caco-2 cells (5×10
5
per well) were plated into 6-well
plates and grown for 24 h. Cells
were then pre-treated with
dexamethasone (1 μM) for 1 h
before stimulation with IL-1β
(1 ng). Cells were harvested at 1
( C X C L 8 )a n d4h( C X C L 1 0 ) ,
total RNA was isolated and
real-time reverse transcription-
polymerase chain reaction was
performed. For measuring
protein expression, stimulation
was performed for 24 h. Data are
shown as the fold increase
compared to the baseline controls
and represent the means of three
individual experiments±standard
error of the mean. Asterisk
corresponds to p<0.05 compared
to controls
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present data confirm earlier observations that colonic
epithelial cells are largely unresponsive to glucocorticoids.
Dexamethasone was not capable of significantly down-
regulating CXCL8 or CXCL10 expression. This is in
accordance with our previous findings showing only an
incomplete transrepression of NFκB activity in transient
reporter gene assays in Caco-2 cells stimulated with IL-1β,
although the level of GR expression in those cells is
comparable to peripheral blood mononuclear cells [20].
Nevertheless, the number of available GR molecules seems
to be insufficient, since transrepression of NFκB can be
restored by GR overexpression [20]. In HT29 cells, there is
a clear lack of GRs, as suggested by the low abundance of
GR mRNA (more than 1,000-fold less than in Caco-2
cells).
In contrast to steroid-sensitive IBD patients, where initial
NFκB activity normalises, NFκB was shown to remain
activated in IECs of IBD patients who are resistant to
steroid therapy [21], suggesting that GR signalling might be
disturbed, possibly due to a lack of functional GRs.
Therefore, inhibiting NFκB with alternative compounds is
of importance in treating IBD. Although 5-aminosalicylic
acid is known to inhibit NFκB[ 22], it is of limited use in
severe ulcerative colitis or Crohn’s disease, and patients do
not profit from its additional oral use when systemic
steroids are given. Although PDTC and BAY11-7082 are
not intended for pharmacological use in humans, they are
paradigms for NFκB inhibitors and are widely used in
experimental settings.
PDTC, a thiol-containing agent, is known to be a stable
anti-oxidant and has been widely used to inhibit the
activation of NFκB in a variety of cell lines. In the present
study, both PDTC and BAY11-7082 inhibited IL-1β-
induced NFκB reporter gene activity in a dose-dependent
manner in Caco-2 cells, revealing their inhibitory effect on
NFκB activation. However, treatment of Caco-2 cells with
PDTC resulted in an dose-dependent enhancement of IL-
1β-induced CXCL8 mRNA expression, rather than its
inhibition, which seems to contradict previous studies that
showed IL-1β was able to induce the CXCL8 gene via
NFκB in Caco-2 cells [23]. ELISA experiments also
showed that this effect was persistent at the level of protein
synthesis and secretion. In contrast, IL-1β-induced CXCL8
expression and secretion were inhibited in a dose-dependent
fashion by BAY11-7082.
Previous studies with PDTC revealed that it is not only
involved in inhibiting NFκB but could also activate other
signalling pathways, depending on the cellular context. In
rat mesangial cells, PDTC induced gene expression of
stromelysin through tyrosine kinase-mediated activation of
the transcription factor AP-1 [24]. Additionally, ICAM-1
expression was upregulated by PDTC in human endothelial
cells via activation of the AP-1 pathway [25]. In vascular
smooth muscle cells, PDTC induced G1 phase cell-cycle
arrest, partially by activating p38 MAPK [26]. Since IL-1β-
induced CXCL8 gene expression was also shown to be
regulated by p38 MAPK via the CXCL8 promoter in Caco-2
cells [27], we aimed to elucidate the role of p38 MAPK in
PDTC- and IL-1β-induced CXCL8 gene expression.
As expected, inhibition of p38 MAPK with the inhibitor
SB205380 led to an inhibition of spontaneous and IL-1β-
induced CXCL8 expression and secretion in Caco-2 cells.
SB203580 inhibited PDTC-mediated enhancement of spon-
taneous and IL-1β-induced CXCL8 expression, suggesting
that PDTC activates the p38 MAPK pathway and,
consequently, CXCL8 gene expression.
These results might be explained by the presence of
single AP-1 binding site in addition to the two NFκB
binding sites in the CXCL8 promoter [28]. Previously, it has
been shown that IL-1β-mediated activation of p38 MAPK
leads to AP-1 activation [29]. In addition to activation of
transcription, post-transcriptional mechanisms contribute to
the induction of CXCL8 gene expression [30]. Holtmann et
al. have shown that the p38 MAP kinase pathway
contributes to induction of CXCL8 synthesis by stabilising
its mRNA [28]. Therefore, the activation of p38 MAPK by
PDTC may lead to an enhancement of IL-1β-induced
CXCL8 gene expression in Caco-2 cells by stabilising
CXCL8 mRNA.
In HT29 cells, PDTC neither inhibited nor enhanced the
IL-1β-induced CXCL8 expression and secretion, whereas
SB203580 and PD98059 had inhibitory effects, suggesting
Fig. 3 Glucocorticoid receptor α mRNA expression in Caco-2 and
HT29 cells. Cells (5×10
5 per well) were plated in 6-well plates, grown
for 24 h and harvested. RNA was isolated and reverse transcribed to
cDNA. Real-time polymerase chain reaction was performed with
gene-specific primers for GRα. β-actin was used as an internal
control. Data shown represent the GRα/β-actin mRNA ratios of four
independent experiments performed in duplicate. The horizontal bars
represent the means
328 Int J Colorectal Dis (2010) 25:323–333that the enhancing effect of PDTC on IL-1β-induced
CXCL8 gene expression as cell-line dependent.
IL-1β is known to induce CXCL10 gene expression in
Caco-2 cells through NFκB[ 7]. To find out if the
enhancing effect of PDTC on IL-1β-induced CXCL8 gene
expression was restricted to the CXCL8 gene, we investi-
gated the role of PDTC on IL-1β-induced CXCL10 gene
expression in Caco-2 and HT29 cells as well. Both real-
time PCR and ELISA experiments revealed that PDTC
inhibited IL-1β-induced CXCL10 gene expression in both
Caco-2 and HT29 cells. The enhancing effect of PD98059
on IL-1β-induced CXCL10 gene expression in HT29 cells
may be a result of the activation of other regulatory
pathways that stabilise CXCL10 mRNA. However, this
effect was not seen at the level of protein synthesis.
Inhibiting the p38 MAPK and MEK pathways resulted in
the inhibition of IL-1β-induced CXCL10 gene expression
in Caco-2 cells.
In conclusion, these data suggest that colonic epithelial
cells are unresponsive to glucocorticoids. Among the tested
compounds, only BAY11-7082 was able to downregulate
CXCL8 and -10 in both cell lines. Although PDTC proved
to inhibit NFκB-driven transcriptional activity, it led to an
increase in CXCL8 expression in Caco-2 cells. This
unexpected phenomenon is most likely due to activation
of p38 MAPK, since it was sensitive to the MAPK inhibitor
Fig. 4 Dose-dependent effects
of pyrrolidine dithiocarbamate
(PDTC) (a) and BAY11-7082
(b) on IL-1β-induced CXCL8
mRNA expression (left panels)
and protein secretion (right
panels) in Caco-2 cells. Caco-2
cells (5×10
5 per well) were
plated in 6-well plates and
grown for 24 h. Cells were then
pre-treated either with 0.2, 2 or
20 μg of PDTC or 1, 10 and
100 μM BAY11-7082 per
millilitre of culture medium for
1 h before stimulation with
IL-1β (1 ng/ml). Cells were
harvested after 1 h, and CXCL8
mRNA expression was
measured by quantitative reverse
transcription-polymerase chain
reaction. For protein measure-
ments, cell supernatants were
collected after 24 h, and
enzyme-linked immunosorbent
serologic assays for CXCL8
protein were performed. Data
shown represent the mean of
four individual experiments±
standard error of the mean
performed in duplicate. Single
asterisk corresponds to p<0.05,
and double asterisks correspond
to p<0.005 compared to IL-1β
stimulation alone
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adjunct to steroid therapy in cases of suspected epithelial
chemokine expression. However, NFκB-inhibiting com-
pounds might activate alternative inflammatory pathways,
as has been shown in the case of PDTC. Therefore, drug-
screeningstrategiesbased purelyonmeasuring NFκBa c t i v i t y
should be regarded cautiously and should include testing for
relevant inflammatory gene products like CXCL8.
Fig. 5 Comparison of the effects of the NFκB inhibitor pyrrolidine
dithiocarbamate (PDTC) and MAP kinase inhibitors SB203580 and
PD98059 on IL-1β-mediated CXCL8 mRNA expression (left panel)
and protein secretion (right panel) in Caco-2 (a) and HT29 (b) cells.
Cells (5×10
5 per well) were plated in 6-well plates and grown for
24 h. Cells were then pre-treated with 20 μg/ml of PDTC, 10 μMo f
SB203580 or 10 μM of PD98059 for 1 h before stimulation with IL-
1β for 4 h (for mRNA expression) or 24 h (for protein levels). CXCL8
mRNA expression was measured by quantitative reverse transcription-
polymerase chain reaction. CXCL8 protein levels were measured from
cell supernatants by enzyme-linked immunosorbent serologic assay.
Data shown represent the mean of four individual experiments±
standard error of the mean performed in duplicate. Asterisk corre-
sponds to p<0.05 compared to IL-1β stimulation, ns not significant
330 Int J Colorectal Dis (2010) 25:323–333Recent studies in mouse conditional knockout models, in
which NFκB signalling was ablated specifically in IECs,
could show that a primary NFκB signalling defect in IECs
disrupts immune homeostasis in the gastrointestinal tract,
causing an inflammatory-bowel-disease-like phenotype
[31], suggesting that a certain level of NFκB activation is
necessary to keep epithelial barrier function. Remarkably
partial disruption of NFκB signalling as achieved by
knocking out IKKβ, one important upstream activator of
NFκB in macrophages resulted in a significant decrease in
tumour size in a mouse model of colitis-associated cancer,
probably by inhibition of paracrine growth factors. In the
same model, IKKβ knockout in enterocytes, although not
abolishing inflammation, prevented development of colonic
cancer, via an increase in apoptosis [32]. Inhibition of
NFκB may therefore be effective in prevention of colitis-
Fig. 6 Comparison of the effects of the NFκB inhibitor pyrrolidine
dithiocarbamate and MAP kinase inhibitors SB203580 and PD98059
on IL-1β-mediated CXCL10 mRNA expression (left panels) and
protein secretion (right panels) in Caco-2 (a) and HT29 (b) cells. Cell
culture and stimulation conditions were as in Fig. 5. CXCL10 mRNA
was measured by quantitative reverse transcription-polymerase chain
reaction and CXCL10 protein by enzyme-linked immunosorbent
serologic assay. Data shown represent the mean of four individual
experiments±standard error of the mean performed in duplicate.
Asterisk corresponds to p<0.05 compared to IL1β alone, number sign
corresponds to p<0.05 compared to unstimulated controls
Int J Colorectal Dis (2010) 25:323–333 331associated cancer. Nevertheless, keeping in mind the
important role of NFκB in promoting intestinal barrier
function and innate immune response care has to be taken
employing NFκB inhibiting compounds in IBD therapy
restricting its use to perpetuating inflammation with a state
of NFκB overactivation.
Open Access This article is distributed under the terms of the Creative
Commons Attribution Noncommercial License which permits any
noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
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